Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CVRX NASDAQ:GUTS NASDAQ:HYPR NASDAQ:NEPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVRXCVRx$5.86+11.6%$6.07$4.37▼$11.30$155.50M0.8266,589 shs791,351 shsGUTSFractyl Health$0.74-7.0%$0.76$0.38▼$2.45$117.88M2.341.72 million shs1.53 million shsHYPRHyperfine$1.48-12.7%$1.49$0.68▼$2.22$145.93M1.38865,747 shs10.90 million shsNEPHNephros$3.61+10.4%$3.31$2.66▼$6.42$39.19M1.5110,736 shs27,725 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVRXCVRx0.00%+18.38%+4.09%-34.23%+0.34%GUTSFractyl Health0.00%-12.07%-11.65%+65.63%-57.30%HYPRHyperfine0.00%-7.81%-7.81%+32.88%+105.57%NEPHNephros0.00%+14.60%-2.43%+24.91%-14.05%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVRXCVRx$5.86+11.6%$6.07$4.37▼$11.30$155.50M0.8266,589 shs791,351 shsGUTSFractyl Health$0.74-7.0%$0.76$0.38▼$2.45$117.88M2.341.72 million shs1.53 million shsHYPRHyperfine$1.48-12.7%$1.49$0.68▼$2.22$145.93M1.38865,747 shs10.90 million shsNEPHNephros$3.61+10.4%$3.31$2.66▼$6.42$39.19M1.5110,736 shs27,725 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVRXCVRx0.00%+18.38%+4.09%-34.23%+0.34%GUTSFractyl Health0.00%-12.07%-11.65%+65.63%-57.30%HYPRHyperfine0.00%-7.81%-7.81%+32.88%+105.57%NEPHNephros0.00%+14.60%-2.43%+24.91%-14.05%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVRXCVRx 3.00Buy$11.5096.25% UpsideGUTSFractyl Health 2.40Hold$5.40626.78% UpsideHYPRHyperfine 2.33Hold$1.7820.90% UpsideNEPHNephros 2.50Moderate Buy$6.0066.20% UpsideCurrent Analyst Ratings BreakdownLatest NEPH, HYPR, CVRX, and GUTS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2026NEPHNephros Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)6/4/2026NEPHNephros Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)6/4/2026GUTSFractyl Health HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.005/21/2026NEPHNephros Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)5/13/2026HYPRHyperfine B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/12/2026GUTSFractyl Health Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/7/2026NEPHNephros Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)5/6/2026CVRXCVRx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/29/2026HYPRHyperfine BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$2.004/24/2026GUTSFractyl Health HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.004/21/2026HYPRHyperfine Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVRXCVRx$56.65M2.75N/AN/A$1.50 per share3.91GUTSFractyl Health$90K1,309.74N/AN/A$0.07 per share10.61HYPRHyperfine$11.40M12.84N/AN/A$0.42 per share3.51NEPHNephros$18.79M2.09$0.13 per share28.78$0.96 per share3.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVRXCVRx-$53.31M-$2.02N/AN/AN/A-89.14%-120.76%-48.38%8/4/2026 (Estimated)GUTSFractyl Health-$140.95M-$1.29N/AN/AN/AN/A-4,053.15%-96.41%8/11/2026 (Estimated)HYPRHyperfine-$35.57M-$0.41N/AN/AN/A-226.88%-98.83%-67.09%8/12/2026 (Estimated)NEPHNephros$1.19M$0.0751.58N/AN/A4.06%7.66%5.86%8/6/2026 (Estimated)Latest NEPH, HYPR, CVRX, and GUTS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026GUTSFractyl Health-$0.17$0.06+$0.23$0.06N/AN/A5/12/2026Q1 2026HYPRHyperfine-$0.09-$0.09N/A-$0.09$3.54 million$3.90 million5/11/2026Q1 2026CVRXCVRx-$0.51-$0.50+$0.01-$0.50$14.49 million$14.77 million5/7/2026Q1 2026NEPHNephros$0.01$0.01N/A$0.01$5.02 million$5.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCVRXCVRxN/AN/AN/AN/AN/AGUTSFractyl HealthN/AN/AN/AN/AN/AHYPRHyperfineN/AN/AN/AN/AN/ANEPHNephrosN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVRXCVRx2.0110.208.89GUTSFractyl Health1.414.284.28HYPRHyperfine0.385.524.90NEPHNephrosN/A4.553.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVRXCVRx75.27%GUTSFractyl HealthN/AHYPRHyperfine15.03%NEPHNephros41.10%Insider OwnershipCompanyInsider OwnershipCVRXCVRx13.90%GUTSFractyl Health8.52%HYPRHyperfine26.33%NEPHNephros6.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVRXCVRx16026.54 million22.85 millionOptionableGUTSFractyl Health102158.65 million145.13 millionN/AHYPRHyperfine19099.27 million73.13 millionOptionableNEPHNephros3010.86 million10.13 millionNot OptionableNEPH, HYPR, CVRX, and GUTS HeadlinesRecent News About These CompaniesNephros Inc.June 24, 2026 | marketwatch.comNephros to Host Virtual Investor Event: “Beyond Filtration: The Nephros Model in Action”June 18, 2026 | globenewswire.comWhy Is Nephros Drawing Attention In The Water Filtration Industry?June 17, 2026 | kalkinemedia.comKNephros Positions Ultrafiltration Technology as a Solution to Emerging Microplastic Risk in WaterJune 17, 2026 | markets.businessinsider.comNephros Earnings Call Balances Growth And Margin PainMay 31, 2026 | theglobeandmail.comUS$7.00 - That's What Analysts Think Nephros, Inc. (NASDAQ:NEPH) Is Worth After These ResultsMay 11, 2026 | finance.yahoo.comNephros (NEPH) Q1 2026 Earnings TranscriptMay 8, 2026 | fool.comNephros, Inc. Q1 2026 Earnings Call SummaryMay 8, 2026 | finance.yahoo.comNephros expects tariff relief from 10% rate to support margins later in 2026May 8, 2026 | seekingalpha.comNephros, Inc. (NEPH) Q1 2026 Earnings Call TranscriptMay 8, 2026 | seekingalpha.comNephros Announces Financial Results for Quarter Ended March 31, 2026May 7, 2026 | globenewswire.com�Nephros Schedules First Quarter 2026 Financial Results Conference CallApril 30, 2026 | prismmediawire.comPNephros Schedules First Quarter 2026 Financial Results Conference CallApril 30, 2026 | globenewswire.comNephros Expands Strategic Focus in Greater New York Market with Dedicated Regional LeadershipApril 16, 2026 | prismmediawire.comPNephros Expands Strategic Focus in Greater New York Market with Dedicated Regional LeadershipApril 16, 2026 | globenewswire.comNephros Insider Trading Activity | NASDAQ:NEPH | BenzingaApril 2, 2026 | benzinga.com�Nephros Expands Water Safety Capabilities With ASSE 12080 Certified Water Management Planning ExpertiseApril 1, 2026 | prismmediawire.comPNephros Expands Water Safety Capabilities With ASSE 12080 Certified Water Management Planning ExpertiseApril 1, 2026 | globenewswire.comNephros Inc. Hits Stride with Groundbreaking Water Safety Solutions in Q4 2025March 19, 2026 | news.themarketisopen.comNNephros, Inc. (NASDAQ:NEPH) Q4 2025 Earnings Call TranscriptMarch 14, 2026 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026SpaceX Rings the Bell and Shatters Every RecordBy Jeffrey Neal Johnson | June 12, 20265 Under-the-Radar AI Stocks to Watch in JuneBy Thomas Hughes | May 31, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 20263 Biotech Firms With Major Potential Catalysts in the Coming MonthsBy Nathan Reiff | June 21, 2026NEPH, HYPR, CVRX, and GUTS Company DescriptionsCVRx NASDAQ:CVRX$5.86 +0.61 (+11.62%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$5.68 -0.18 (-3.07%) As of 06/26/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Fractyl Health NASDAQ:GUTS$0.74 -0.06 (-7.00%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$0.77 +0.03 (+3.50%) As of 06/26/2026 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.Hyperfine NASDAQ:HYPR$1.48 -0.22 (-12.72%) Closing price 06/26/2026 03:59 PM EasternExtended Trading$1.55 +0.08 (+5.08%) As of 06/26/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.Nephros NASDAQ:NEPH$3.61 +0.34 (+10.40%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$3.61 0.00 (0.00%) As of 06/26/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/22 - 06/26 Rocket Lab's NASA Win Tests Key Support After Sharp Pullback 3 ETFs Pairing Market-Beating Returns With High Dividend Yields BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone SpaceX Has Real Value—But These 3 Stocks Have Better Odds Right Now Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout 3 Stocks That Could Benefit as the Robotaxi Race Heats Up Palantir’s Valuation Problem Just Met 2 New Growth Catalysts Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
